

Vivek Subbiah

List of Publications by Citations

Source: <https://exaly.com/author-pdf/5298288/vivek-subbiah-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

399
papers

10,478
citations

47
h-index

91
g-index

461
ext. papers

14,174
ext. citations

6.4
avg, IF

6.43
L-index

#	Paper	IF	Citations
399	Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. <i>New England Journal of Medicine</i> , 2015 , 373, 726-36	59.2	1172
398	Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. <i>Lancet, The</i> , 2020 , 395, 1907-1918	41.8880	18880
397	Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer. <i>Journal of Clinical Oncology</i> , 2018 , 36, 7-13	2.2	376
396	Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. <i>New England Journal of Medicine</i> , 2007 , 357, 1916-27	59.2	324
395	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017 , 23, 1388-1396	12.9	199
394	Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 813-824	59.2	194
393	Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. <i>JAMA Oncology</i> , 2018 , 4, 384-388	13.4	191
392	Precision Targeted Therapy with BLU-667 for -Driven Cancers. <i>Cancer Discovery</i> , 2018 , 8, 836-849	24.4	189
391	Selective RET kinase inhibition for patients with RET-altered cancers. <i>Annals of Oncology</i> , 2018 , 29, 1869-1876	18.36	184
390	Efficacy of Selpercatinib in -Altered Thyroid Cancers. <i>New England Journal of Medicine</i> , 2020 , 383, 825-835	59.2	166
389	Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study. <i>Cancer Research</i> , 2016 , 76, 3690-701	10.1	154
388	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation. <i>Cancer Discovery</i> , 2016 , 6, 1352-1365	24.4	150
387	BRAF Inhibition in -Mutant Gliomas: Results From the VE-BASKET Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 3477-3484	2.2	139
386	Of mice and men: divergent risks of teriparatide-induced osteosarcoma. <i>Osteoporosis International</i> , 2010 , 21, 1041-5	5.3	130
385	Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. <i>Lancet Oncology, The</i> , 2020 , 21, 1234-1243	21.7	120
384	Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients. <i>Clinical Cancer Research</i> , 2017 , 23, 1988-1997	12.9	112
383	Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. <i>Annals of Oncology</i> , 2016 , 27, 795-800	10.3	107

382	Ewing's sarcoma: standard and experimental treatment options. <i>Current Treatment Options in Oncology</i> , 2009 , 10, 126-40	5.4	107
381	Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. <i>Investigational New Drugs</i> , 2018 , 36, 638-646	4.3	102
380	Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. <i>Lancet Oncology</i> , 2020 , 21, 645-654	21.7	99
379	Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab. <i>JAMA Oncology</i> , 2017 , 3, 509-515	13.4	97
378	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 181-188	12.9	89
377	State-of-the-Art Strategies for Targeting -Dependent Cancers. <i>Journal of Clinical Oncology</i> , 2020 , 38, 1209-1221	2.2	83
376	RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies. <i>Journal of Thoracic Oncology</i> , 2020 , 15, 541-549	8.9	83
375	A phase 1 study of LOXO-292, a potent and highly selective RET inhibitor, in patients with RET-altered cancers. <i>Journal of Clinical Oncology</i> , 2018 , 36, 102-102	2.2	72
374	Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials 2017 , 5, 100		67
373	Hotspot mutation panel testing reveals clonal evolution in a study of 265 paired primary and metastatic tumors. <i>Clinical Cancer Research</i> , 2015 , 21, 2644-51	12.9	63
372	Clinical activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients (pts) with advanced RET-fusion+ non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2019 , 37, 9008-9008	2.2	62
371	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 1397-404	6.1	61
370	Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations. <i>Cancer</i> , 2016 , 122, 702-11	6.4	61
369	Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification. <i>Annals of Oncology</i> , 2018 , 29, 1445-1453	10.3	60
368	COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2021 , 18, 313-319	19.4	59
367	Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. <i>Investigational New Drugs</i> , 2018 , 36, 601-607	4.3	58
366	Targeted morphoproteomic profiling of Ewing's sarcoma treated with insulin-like growth factor 1 receptor (IGF1R) inhibitors: response/resistance signatures. <i>PLoS ONE</i> , 2011 , 6, e18424	3.7	58
365	Phase Ib/II Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2018 , 24, 43-51	12.9	57

364	The Marriage Between Genomics and Immunotherapy: Mismatch Meets Its Match. <i>Oncologist</i> , 2019 , 24, 1-3	5.7	57
363	First-in-human phase I study of SOR-C13, a TRPV6 calcium channel inhibitor, in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2017 , 35, 324-333	4.3	56
362	STUMP un"stumped": anti-tumor response to anaplastic lymphoma kinase (ALK) inhibitor based targeted therapy in uterine inflammatory myofibroblastic tumor with myxoid features harboring DCTN1-ALK fusion. <i>Journal of Hematology and Oncology</i> , 2015 , 8, 66	22.4	56
361	Clinical Development of BRAF plus MEK Inhibitor Combinations. <i>Trends in Cancer</i> , 2020 , 6, 797-810	12.5	56
360	Evaluation of 122 advanced-stage cutaneous squamous cell carcinomas by comprehensive genomic profiling opens the door for new routes to targeted therapies. <i>Cancer</i> , 2016 , 122, 249-57	6.4	53
359	Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms. <i>Oncotarget</i> , 2014 , 5, 2349-54	3.3	50
358	TP53 Alterations Correlate with Response to VEGF/VEGFR Inhibitors: Implications for Targeted Therapeutics. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 2475-2485	6.1	49
357	Systemic and CNS activity of the RET inhibitor vandetanib combined with the mTOR inhibitor everolimus in KIF5B-RET re-arranged non-small cell lung cancer with brain metastases. <i>Lung Cancer</i> , 2015 , 89, 76-9	5.9	48
356	Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2021 , 22, 959-969	21.7	48
355	Advances in Targeting RET-Dependent Cancers. <i>Cancer Discovery</i> , 2020 , 10, 498-505	24.4	47
354	Targeted therapy by combined inhibition of the RAF and mTOR kinases in malignant spindle cell neoplasm harboring the KIAA1549-BRAF fusion protein. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 8	22.4	47
353	Targeting the apoptotic pathway in chondrosarcoma using recombinant human Apo2L/TRAIL (dulcanermin), a dual proapoptotic receptor (DR4/DR5) agonist. <i>Molecular Cancer Therapeutics</i> , 2012 , 11, 2541-6	6.1	47
352	Pan-Cancer Efficacy of Vemurafenib in -Mutant Non-Melanoma Cancers. <i>Cancer Discovery</i> , 2020 , 10, 657-663	6.1	46
351	Genomically Driven Tumors and Actionability across Histologies: BRAF-Mutant Cancers as a Paradigm. <i>Molecular Cancer Therapeutics</i> , 2016 , 15, 533-47	6.1	46
350	Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations. <i>Annals of Oncology</i> , 2021 , 32, 261-268	10.3	46
349	Phase 2 study of pembrolizumab in patients with advanced rare cancers 2020 , 8,		45
348	Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2017 , 23, 3657-3666 ^{12.9}	12.9	44
347	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiation-Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019 , 7, 1903-1909	12.5	44

346	Hyperprogression and Immunotherapy: Fact, Fiction, or Alternative Fact?. <i>Trends in Cancer</i> , 2020 , 6, 181-191	12.9	43
345	Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. <i>Clinical Cancer Research</i> , 2018 , 24, 4865-4873	12.9	43
344	The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. <i>British Journal of Cancer</i> , 2017 , 116, 1402-1407	8.7	42
343	Resistance to mammalian target of rapamycin inhibitor therapy in perivascular epithelioid cell tumors. <i>Journal of Clinical Oncology</i> , 2010 , 28, e415	2.2	42
342	FBXW7 mutations in patients with advanced cancers: clinical and molecular characteristics and outcomes with mTOR inhibitors. <i>PLoS ONE</i> , 2014 , 9, e89388	3.7	42
341	Phase I clinical trial of combination imatinib and ipilimumab in patients with advanced malignancies 2017 , 5, 35		41
340	Theranostic Profiling for Actionable Aberrations in Advanced High Risk Osteosarcoma with Aggressive Biology Reveals High Molecular Diversity: The Human Fingerprint Hypothesis. <i>Oncoscience</i> , 2014 , 1, 167-179	0.8	41
339	Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study. <i>Lancet Diabetes and Endocrinology</i> , 2021 , 9, 491-501	18.1	41
338	Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. <i>Annals of Oncology</i> , 2015 , 26, 1012-1018	10.3	40
337	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials. <i>Cancer</i> , 2016 , 122, 3401-3409	6.4	40
336	Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3480-8	2.2	40
335	Development and Validation of an Ultradeep Next-Generation Sequencing Assay for Testing of Plasma Cell-Free DNA from Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 5648-5656	12.9	38
334	Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas. <i>Oncotarget</i> , 2017 , 8, 39254-39267	3.3	38
333	Clinical next generation sequencing to identify actionable aberrations in a phase I program. <i>Oncotarget</i> , 2015 , 6, 20099-110	3.3	38
332	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015 , 6, 26886-94	3.3	38
331	Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating Alterations and Oncogenic Signaling Pathway Aberrations. <i>Clinical Cancer Research</i> , 2019 , 25, 5832-5842	12.9	37
330	Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. <i>Advances in Experimental Medicine and Biology</i> , 2014 , 804, 291-304	3.6	37
329	Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 83, 317-26	4	37

328	Treatment of patients with advanced neurofibromatosis type 2 with novel molecularly targeted therapies: from bench to bedside. <i>Journal of Clinical Oncology</i> , 2012 , 30, e64-8	2.2	37
327	Outcomes of splenectomy in T-cell large granular lymphocyte leukemia with splenomegaly and cytopenia. <i>Experimental Hematology</i> , 2008 , 36, 1078-83	3.1	37
326	Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 109-109	2.2	37
325	Personalized comprehensive molecular profiling of high risk osteosarcoma: Implications and limitations for precision medicine. <i>Oncotarget</i> , 2015 , 6, 40642-54	3.3	37
324	Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials. <i>Annals of Oncology</i> , 2018 , 29, 2396-2398	10.3	37
323	Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy. <i>Oncotarget</i> , 2016 , 7, 67521-67531	3.3	36
322	Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction. <i>Annals of Oncology</i> , 2017 , 28, 642-650	10.3	35
321	Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities. <i>Orphanet Journal of Rare Diseases</i> , 2013 , 8, 112	4.2	34
320	IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. <i>Journal of the National Cancer Institute</i> , 2016 , 108,	9.7	33
319	Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR response. <i>BMC Cancer</i> , 2015 , 15, 713	4.8	33
318	Phase 1 clinical trials for sarcomas: the cutting edge. <i>Current Opinion in Oncology</i> , 2011 , 23, 352-60	4.2	31
317	Morphoproteomic profiling of the mammalian target of rapamycin (mTOR) signaling pathway in desmoplastic small round cell tumor (EWS/WT1), Ewing's sarcoma (EWS/FLI1) and Wilms' tumor(WT1). <i>PLoS ONE</i> , 2013 , 8, e68985	3.7	30
316	Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives. <i>Diagnostics</i> , 2017 , 7,	3.8	29
315	Activity and tolerability of BLU-667, a highly potent and selective RET inhibitor, in patients with advanced RET-altered thyroid cancers.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 6018-6018	2.2	29
314	Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. <i>Oncotarget</i> , 2013 , 4, 156-65	3.3	29
313	Myeloid/lymphoid neoplasms with FGFR1 rearrangement. <i>Leukemia and Lymphoma</i> , 2018 , 59, 1672-1676	1.9	29
312	Alpha Emitter Radium 223 in High-Risk Osteosarcoma: First Clinical Evidence of Response and Blood-Brain Barrier Penetration. <i>JAMA Oncology</i> , 2015 , 1, 253-5	13.4	28
311	Clinical activity of ceritinib in ROS1-rearranged non-small cell lung cancer: Bench to bedside report. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, E1419-20	11.5	28

310	Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. <i>PLoS ONE</i> , 2014 , 9, e93676	3.7	28
309	Phase I dose escalation study of temsirolimus in combination with metformin in patients with advanced/refractory cancers. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 77, 973-7	3.5	28
308	Phase Ib/II Study of the Safety and Efficacy of Combination Therapy with Multikinase VEGF Inhibitor Pazopanib and MEK Inhibitor Trametinib In Advanced Soft Tissue Sarcoma. <i>Clinical Cancer Research</i> , 2017 , 23, 4027-4034	12.9	27
307	The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope. <i>Current Oncology Reports</i> , 2017 , 19, 78	6.3	27
306	Comprehensive Genomic Profiling of Clinically Advanced Medullary Thyroid Carcinoma. <i>Oncology</i> , 2016 , 90, 339-46	3.6	27
305	From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm. <i>Trends in Cancer</i> , 2021 , 7, 15-28	12.5	27
304	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1924-1931	12.9	26
303	Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. <i>Journal of Surgical Oncology</i> , 2010 , 101, 327-33	2.8	26
302	OA12.07 Clinical Activity of LOXO-292, a Highly Selective RET Inhibitor, in Patients with RET Fusion+ Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018 , 13, S349-S350	8.9	26
301	Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. <i>Oncologist</i> , 2018 , 23, 360-366	5.7	25
300	Analysis of MET genetic aberrations in patients with breast cancer at MD Anderson Phase I unit. <i>Clinical Breast Cancer</i> , 2014 , 14, 468-74	3	25
299	Next generation sequencing analysis of platinum refractory advanced germ cell tumor sensitive to Sunitinib (Sutent®) a VEGFR2/PDGFR/c-kit/ FLT3/RET/CSF1R inhibitor in a phase II trial. <i>Journal of Hematology and Oncology</i> , 2014 , 7, 52	22.4	25
298	Treatment with Combination of Dabrafenib and Trametinib in Patients with Recurrent/Refractory BRAF V600E-Mutated Hairy Cell Leukemia (HCL). <i>Blood</i> , 2018 , 132, 391-391	2.2	25
297	A framework for genomic biomarker actionability and its use in clinical decision making. <i>Oncoscience</i> , 2014 , 1, 614-623	0.8	25
296	Alpha Particle Radium 223 Dichloride in High-risk Osteosarcoma: A Phase I Dose Escalation Trial. <i>Clinical Cancer Research</i> , 2019 , 25, 3802-3810	12.9	24
295	Gastric adenocarcinoma in children and adolescents. <i>Pediatric Blood and Cancer</i> , 2011 , 57, 524-7	3	24
294	MET aberrations and c-MET inhibitors in patients with gastric and esophageal cancers in a phase I unit. <i>Oncotarget</i> , 2014 , 5, 1837-45	3.3	24
293	A novel immunomodulatory molecularly targeted strategy for refractory Hodgkin's lymphoma. <i>Oncotarget</i> , 2014 , 5, 95-102	3.3	23

292	Phase I Dose-Escalation Study of Anti-CTLA-4 Antibody Ipilimumab and Lenalidomide in Patients with Advanced Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 671-676	6.1	23
291	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. <i>Lung Cancer</i> , 2018 , 120, 137-141	5.9	22
290	Challenging Standard-of-Care Paradigms in the Precision Oncology Era. <i>Trends in Cancer</i> , 2018 , 4, 101-109	2.5	22
289	Dabrafenib plus trametinib in patients with BRAF-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trial. <i>Lancet Oncology</i> , 2021 ,	21.7	22
288	Activity of c-Met/ALK Inhibitor Crizotinib and Multi-Kinase VEGF Inhibitor Pazopanib in Metastatic Gastrointestinal Neuroectodermal Tumor Harboring EWSR1-CREB1 Fusion. <i>Oncology</i> , 2016 , 91, 348-353	3.6	21
287	Radium-223 dichloride bone-targeted alpha particle therapy for hormone-refractory breast cancer metastatic to bone. <i>Experimental Hematology and Oncology</i> , 2014 , 3, 23	7.8	21
286	Targeted Therapy of Ewing's Sarcoma. <i>Sarcoma</i> , 2011 , 2011, 686985	3.1	21
285	Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. <i>JAMA Oncology</i> , 2016 , 2, 719-20	13.4	21
284	Debunking the Delusion That Precision Oncology Is an Illusion. <i>Oncologist</i> , 2017 , 22, 881-882	5.7	19
283	Managing Cancer Care during the COVID-19 Pandemic and Beyond. <i>Trends in Cancer</i> , 2020 , 6, 533-535	12.5	19
282	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017 , 2,	9.9	19
281	Cytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 3845-3856	12.9	19
280	Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus. <i>Oncotarget</i> , 2016 , 7, 23227-38	3.3	19
279	Analysis of Amplification: Next-Generation Sequencing of Patients With Diverse Malignancies. <i>JCO Precision Oncology</i> , 2018 , 2018,	3.6	19
278	Clinical Next-Generation Sequencing for Precision Oncology in Rare Cancers. <i>Molecular Cancer Therapeutics</i> , 2018 , 17, 1595-1601	6.1	18
277	[90Y]yttrium microspheres radioembolotherapy in desmoplastic small round cell tumor hepatic metastases. <i>Journal of Clinical Oncology</i> , 2011 , 29, e292-4	2.2	18
276	Abstract CT043: Highly potent and selective RET inhibitor, BLU-667, achieves proof of concept in a phase I study of advanced,RET-altered solid tumors 2018 ,		18
275	First-in-human phase 1 study of ETC-159 an oral PORCN inhibitor in patients with advanced solid tumours.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2584-2584	2.2	18

274	Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implications. <i>Oncotarget</i> , 2013 , 4, 884-93	18
273	Outcomes of patients with sarcoma enrolled in clinical trials of pazopanib combined with histone deacetylase, mTOR, Her2, or MEK inhibitors. <i>Scientific Reports</i> , 2017 , 7, 15963	4.9 17
272	Immunotherapy in non-small cell lung cancer harbouring driver mutations. <i>Cancer Treatment Reviews</i> , 2021 , 96, 102179	14.4 17
271	MET abnormalities in patients with genitourinary malignancies and outcomes with c-MET inhibitors. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e19-26	3.3 16
270	Development of a prognostic scoring system for patients with advanced cancer enrolled in immune checkpoint inhibitor phase 1 clinical trials. <i>British Journal of Cancer</i> , 2018 , 118, 763-769	8.7 16
269	Counterpoint: Successes in the Pursuit of Precision Medicine: Biomarkers Take Credit. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017 , 15, 863-866	7.3 16
268	Phase 2 5-Arm Trial of Ipilimumab Plus Lung or Liver Stereotactic Radiation for Patients with Advanced Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017 , 99, 1315	4 16
267	Next generation sequencing of carcinoma of unknown primary reveals novel combinatorial strategies in a heterogeneous mutational landscape. <i>Oncoscience</i> , 2017 , 4, 47-56	0.8 16
266	Ewing's sarcoma: overcoming the therapeutic plateau. <i>Discovery Medicine</i> , 2012 , 13, 405-15	2.5 16
265	EGFR and HER2 exon 20 insertions in solid tumours: from biology to treatment. <i>Nature Reviews Clinical Oncology</i> , 2021 ,	19.4 16
264	The Master Observational Trial: A New Class of Master Protocol to Advance Precision Medicine. <i>Cell</i> , 2020 , 180, 9-14	56.2 16
263	Treatment of the myeloid/lymphoid neoplasm with FGFR1 rearrangement with FGFR1 inhibitor. <i>Annals of Oncology</i> , 2018 , 29, 1880-1882	10.3 16
262	Efficacy of Vemurafenib in Patients With Non-Small-Cell Lung Cancer With V600 Mutation: An Open-Label, Single-Arm Cohort of the Histology-Independent VE-BASKET Study. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6 15
261	The next-generation RET inhibitor TPX-0046 is active in drug-resistant and naïve RET-driven cancer models.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3616-3616	2.2 15
260	Prevalence of MDM2 amplification and coalterations in 523 advanced cancer patients in the MD Anderson phase 1 clinic. <i>Oncotarget</i> , 2018 , 9, 33232-33243	3.3 15
259	Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. <i>ESMO Open</i> , 2020 , 5, e000799	6 15
258	Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors. <i>ESMO Open</i> , 2020 , 5,	6 15
257	Neoadjuvant selpercatinib for advanced medullary thyroid cancer. <i>Head and Neck</i> , 2021 , 43, E7-E12	4.2 15

256	Mesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven Biology. <i>Current Oncology Reports</i> , 2018 , 20, 37	6.3	14
255	Efficacy of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutated anaplastic thyroid cancer (ATC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 6023-6023	2.2	14
254	Phase II Clinical Trial of Pembrolizumab in Patients with Progressive Metastatic Pheochromocytomas and Paragangliomas. <i>Cancers</i> , 2020 , 12,	6.6	14
253	Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer. <i>Investigational New Drugs</i> , 2018 , 36, 416-423	4.3	13
252	Calcinosis cutis dermatologic toxicity associated with fibroblast growth factor receptor inhibitor for the treatment of Wilms tumor. <i>Journal of Cutaneous Pathology</i> , 2018 , 45, 786-790	1.7	13
251	Radium-223 dichloride therapy in breast cancer with osseous metastases. <i>BMJ Case Reports</i> , 2015 , 2015,	0.9	13
250	Progresses Toward Precision Medicine in -altered Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 6102-6111	6.1	13
249	Updated efficacy and safety data of dabrafenib (D) and trametinib (T) in patients (pts) with BRAF V600E mutated anaplastic thyroid cancer (ATC). <i>Annals of Oncology</i> , 2018 , 29, viii645-viii646	10.3	13
248	MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. <i>Cancers</i> , 2019 , 11,	6.6	12
247	Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST. <i>ESMO Open</i> , 2019 , 4, e000439	6	12
246	Rapid response to therapy of neurocutaneous melanosis with leptomeningeal melanoma. <i>Pediatric Blood and Cancer</i> , 2010 , 54, 180-1	3	12
245	Tissue is the issue-sarcoidosis following ABVD chemotherapy for Hodgkin's lymphoma: a case report. <i>Journal of Medical Case Reports</i> , 2007 , 1, 148	1.2	12
244	Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 9516-9516	2.2	12
243	Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. <i>Oncotarget</i> , 2016 , 7, 64421-64430	3.3	12
242	Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 4160-4167	12.9	12
241	Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. <i>Cancer Medicine</i> , 2016 , 5, 3437-3444	4.8	12
240	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy. <i>Investigational New Drugs</i> , 2015 , 33, 700-9	4.3	11
239	Photoallergic reaction in a patient receiving vandetanib for metastatic follicular thyroid carcinoma: a case report. <i>BMC Dermatology</i> , 2015 , 15, 2	2.1	11

238	Bilateral gonadoblastoma with dysgerminoma and pilocytic astrocytoma with WT1 GT-IVS9 mutation: A 46 XY phenotypic female with Frasier syndrome. <i>Pediatric Blood and Cancer</i> , 2009 , 53, 1349-51	3.1	11
237	Clinical next generation sequencing of pediatric-type malignancies in adult patients identifies novel somatic aberrations. <i>Oncoscience</i> , 2015 , 2, 187-92	0.8	11
236	Targeted therapy for genetic cancer syndromes: Von Hippel-Lindau disease, Cowden syndrome, and Proteus syndrome. <i>Discovery Medicine</i> , 2015 , 19, 109-16	2.5	11
235	IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. <i>Cancers</i> , 2020 , 12,	6.6	10
234	EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2604-TPS2604	2.2	10
233	First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 3556-3566	12.9	10
232	A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. <i>Clinical Cancer Research</i> , 2019 , 25, 5475-5484	12.9	9
231	Genomics, Morphoproteomics, and Treatment Patterns of Patients with Alveolar Soft Part Sarcoma and Response to Multiple Experimental Therapies. <i>Molecular Cancer Therapeutics</i> , 2020 , 19, 1165-1172	6.1	9
230	Co-occurring Genomic Alterations and Association With Progression-Free Survival in BRAFV600-Mutated Nonmelanoma Tumors. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	9
229	Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinic. <i>Clinical Cancer Research</i> , 2014 , 20, 5956-63	12.9	9
228	A tale of two histiocytic disorders. <i>Oncologist</i> , 2013 , 18, 2-4	5.7	9
227	Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3511-3511	2.2	9
226	Significant systemic and CNS activity of RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with advanced NSCLC with RET fusion.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9069-9069 ⁹	2.2	9
225	Efficacy of vemurafenib in patients (pts) with non-small cell lung cancer (NSCLC) with BRAFV600 mutation.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 9074-9074	2.2	9
224	Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience. <i>Oncotarget</i> , 2016 , 7, 35132-43	3.3	9
223	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. <i>Journal of Medical Internet Research</i> , 2019 , 21, e10348	7.6	9
222	Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. <i>Scientific Reports</i> , 2016 , 6, 35448	4.9	9
221	Precision therapy for RET-altered cancers with RET inhibitors. <i>Trends in Cancer</i> , 2021 , 7, 1074-1088	12.5	9

220	Systemic and CNS Activity of Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With RET-Mutant Medullary Thyroid Cancer With Extensive CNS Metastases. <i>JCO Precision Oncology</i> , 2020 , 4,	3.6	8
219	Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial. <i>Experimental Hematology and Oncology</i> , 2020 , 9, 7	7.8	8
218	Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy. <i>Journal of Immunotherapy</i> , 2018 , 41, 284-291	5	8
217	Killing two birds with one stone: BRAF V600E inhibitor therapy for hairy cell leukemia and Langerhans/dendritic cell sarcoma. <i>Annals of Hematology</i> , 2013 , 92, 1149	3	8
216	Abstract CT091: Safety and pharmacodynamic activity of MEDI9197, a TLR 7/8 agonist, administered intratumorally in subjects with solid tumors 2017 ,		8
215	A first-in-human phase I study of VGX-100, a selective anti-VEGF-C antibody, alone and in combination with bevacizumab in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2524-2524	2.2	8
214	Multi-kinase RET inhibitor vandetanib combined with mTOR inhibitor everolimus in patients with RET rearranged non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 9035-9035	2.2	8
213	Exploring response signals and targets in aggressive unresectable hepatocellular carcinoma: an analysis of targeted therapy phase 1 trials. <i>Oncotarget</i> , 2015 , 6, 28453-62	3.3	8
212	A global effort to understand the riddles of COVID-19 and cancer.. <i>Nature Cancer</i> , 2020 , 1, 943-945	15.4	8
211	Testing for COVID-19 in patients with cancer. <i>EClinicalMedicine</i> , 2020 , 23, 100374	11.3	8
210	Mining Public Databases for Precision Oncology. <i>Trends in Cancer</i> , 2018 , 4, 463-465	12.5	8
209	Unique Aberrations in Intimal Sarcoma Identified by Next-Generation Sequencing as Potential Therapy Targets. <i>Cancers</i> , 2019 , 11,	6.6	7
208	Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (F-FLT) PET/CT in Lung Cancer. <i>Diagnostics</i> , 2020 , 10,	3.8	7
207	223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy. <i>ESMO Open</i> , 2020 , 5,	6	7
206	Prospects and pitfalls of personalizing therapies for sarcomas: from children, adolescents, and young adults to the elderly. <i>Current Oncology Reports</i> , 2014 , 16, 401	6.3	7
205	Abstract CT111: Preliminary results from a phase 1/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies 2017 ,		7
204	Checkpoint kinase (CHK) 1/2 inhibitor LY2606368 in a phase I, dose-expansion study in patients (pts) with metastatic squamous cell carcinoma (mSCC) of the anus.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3520-3520	2.2	7
203	Clinical next-generation sequencing reveals aggressive cancer biology in adolescent and young adult patients. <i>Oncoscience</i> , 2015 , 2, 646-58	0.8	7

202	Progression-free survival is a suboptimal predictor for overall survival among metastatic solid tumour clinical trials. <i>European Journal of Cancer</i> , 2020 , 136, 176-185	7.5	7
201	A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2021 , 27, 3050-3060	12.9	7
200	The L730V/I RET roof mutations display different activities toward pralsetinib and selpercatinib. <i>Npj Precision Oncology</i> , 2021 , 5, 48	9.8	7
199	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019 , 125, 463-472	6.4	7
198	Pembrolizumab in Patients with Advanced Metastatic Germ Cell Tumors. <i>Oncologist</i> , 2021 , 26, 558-e1098	9.7	7
197	High-Throughput Architecture for Discovering Combination Cancer Therapeutics. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-12	5.2	7
196	Targeted therapy for hereditary cancer syndromes: hereditary breast and ovarian cancer syndrome, Lynch syndrome, familial adenomatous polyposis, and Li-Fraumeni syndrome. <i>Discovery Medicine</i> , 2014 , 18, 331-9	2.5	7
195	Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma. <i>Case Reports in Oncology</i> , 2019 , 12, 7-13	1	6
194	Hypopigmented Skin Lesions After Immunotherapy. <i>JAMA Oncology</i> , 2018 , 4, 1118-1119	13.4	6
193	Combined Antiangiogenic and Mammalian Target of Rapamycin Inhibitor Targeted Therapy in Metaplastic Breast Cancer Harboring a PIK3CA Mutation. <i>Journal of Breast Cancer</i> , 2014 , 17, 287-90	3	6
192	Adolescent oncology: who cares?-the new KID on the block. <i>Supportive Care in Cancer</i> , 2010 , 18, 771-3	3.9	6
191	Clinical characteristics and outcomes of pediatric oncology patients with aggressive biology enrolled in phase I clinical trials designed for adults: the university of Texas MD anderson cancer center experience. <i>Oncoscience</i> , 2014 , 1, 522-530	0.8	6
190	Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies. <i>British Journal of Cancer</i> , 2021 , 124, 1533-1539	8.7	6
189	Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer. <i>Annals of Oncology</i> , 2021 , 32, 817-819	10.3	6
188	Precision Oncology for Hepatocellular Cancer: Slivering the Liver by FGF19-FGF4-KLB Pathway Inhibition. <i>Cancer Discovery</i> , 2019 , 9, 1646-1649	24.4	6
187	Abstract CT024: Results of a phase I dose escalation study of ARQ 751 in adult subjects with advanced solid tumors with AKT1, 2, 3 genetic alterations, activating PI3K mutations, PTEN-null, or other known actionable PTEN mutations 2018 ,		5
186	Prospective study comparing outcomes in patients with advanced malignancies on molecular alteration-matched versus non-matched therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11019-11019	2.2	5
185	Phase II study of the PARP inhibitor talazoparib (BMN-673) in advanced cancer patients with somatic alterations in BRCA1/2, mutations/deletions in PTEN or PTEN loss, a homologous recombination defect, mutations/deletions in other BRCA pathway genes and germline mutation S in BRCA1/2 (not breast or ovarian cancer). <i>Journal of Clinical Oncology</i> , 2015 , 33, TPS2117-TPS2117	2.2	5

184	Alpha particle radium-223 dichloride ($^{223}\text{RaCl}_2$) in high risk osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11029-11029	2.2	5
183	Genomic mutation profiling (GMP) and clinical outcome in patients (pts) treated with ribociclib (CDK4/6 inhibitor) in the Signature program.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2528-2528	2.2	5
182	Safety, toxicity and activity of multi-kinase inhibitor vandetanib in combination with everolimus in advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9073-9073	2.2	5
181	Comparative Effectiveness of Atezolizumab, Nivolumab, and Docetaxel in Patients With Previously Treated Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021 , 4, e2134299	10.4	5
180	Novel use of a Clinical Laboratory Improvements Amendments (CLIA)-certified Cyclin-Dependent Kinase N2C (CDKN2C) loss assay in sporadic medullary thyroid carcinoma. <i>Surgery</i> , 2020 , 167, 80-86	3.6	5
179	Safety and Efficacy of Vorinostat Plus Sirolimus or Everolimus in Patients with Relapsed Refractory Hodgkin Lymphoma. <i>Clinical Cancer Research</i> , 2020 , 26, 5579-5587	12.9	5
178	Antitumor activity of lurbinectedin in second-line small cell lung cancer patients who are candidates for re-challenge with the first-line treatment. <i>Lung Cancer</i> , 2020 , 150, 90-96	5.9	5
177	Phase I Study of P-cadherin-targeted Radioimmunotherapy with Y-FF-21101 Monoclonal Antibody in Solid Tumors. <i>Clinical Cancer Research</i> , 2020 , 26, 5830-5842	12.9	5
176	Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical Trials. <i>Oncologist</i> , 2021 , 26, 588-596	5.7	5
175	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. <i>JCO Clinical Cancer Informatics</i> , 2018 , 2, 1-14	5.2	5
174	Autoimmune hypophysitis. <i>Lancet Oncology, The</i> , 2018 , 19, e123	21.7	4
173	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in patients with advanced cancers. <i>British Journal of Cancer</i> , 2018 , 118, 1419-1424	8.7	4
172	Jaundice (Hyperbilirubinemia) in Cancer. <i>JAMA Oncology</i> , 2016 , 2, 1103	13.4	4
171	Elevated maternal lipoprotein (a) and neonatal renal vein thrombosis: a case report. <i>Journal of Medical Case Reports</i> , 2008 , 2, 106	1.2	4
170	ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E-mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy.. <i>Journal of Clinical Oncology</i> , 2016 , 34, TPS2604-TPS2604	2.2	4
169	Effect of adenoviral p53 (Ad-p53) tumor suppressor immune gene therapy on checkpoint inhibitor resistance and abscopal therapeutic efficacy.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14610-e14610	2.2	4
168	Efficacy and safety of lurbinectedin (PM1183) in Ewing sarcoma: Final results from a phase 2 study.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 11519-11519	2.2	4
167	Outcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancer. <i>Oncotarget</i> , 2018 , 9, 33258-33270	3.3	4

166	COVID-19 Pandemic and Cancer Clinical Trial Pandemonium: Finding the Silver Lining. <i>Journal of Immunotherapy and Precision Oncology</i> , 2021 , 4, 64-66	0.6	4
165	Imaging of acute abdomen in cancer patients. <i>Abdominal Radiology</i> , 2020 , 45, 2287-2304	3	4
164	Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	4
163	Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors 2021 , 9,		4
162	Phase I Study of the BRAF Inhibitor Vemurafenib in Combination With the Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With -Mutated Malignancies. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	4
161	A phase I clinical trial of hepatic arterial infusion of oxaliplatin and oral capecitabine, with or without intravenous bevacizumab, in patients with advanced cancer and predominant liver involvement. <i>Cancer Chemotherapy and Pharmacology</i> , 2018 , 82, 877-885	3.5	4
160	Hallmarks of RET and Co-occurring Genomic Alterations in -aberrant Cancers. <i>Molecular Cancer Therapeutics</i> , 2021 , 20, 1769-1776	6.1	4
159	Targeted therapy for hereditary cancer syndromes: neurofibromatosis type 1, neurofibromatosis type 2, and Gorlin syndrome. <i>Discovery Medicine</i> , 2014 , 18, 323-30	2.5	4
158	Precision Oncology in Sarcomas: Divide and Conquer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
157	Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. <i>Scientific Reports</i> , 2020 , 10, 3080	4.9	3
156	Cannabidiol (CBD) Oil, Cancer, and Symptom Management: A Google Trends Analysis of Public Interest. <i>Journal of Alternative and Complementary Medicine</i> , 2020 , 26, 346-348	2.4	3
155	An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography F-FLT PET/CT in Prostate Adenocarcinoma. <i>Diagnostics</i> , 2017 , 7,	3.8	3
154	Insurance Clearance for Early-Phase Oncology Clinical Trials Following the Affordable Care Act. <i>Clinical Cancer Research</i> , 2017 , 23, 4155-4162	12.9	3
153	Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit. <i>Oncology</i> , 2017 , 92, 14-20	3.6	3
152	Cognitive Changes During Chemotherapy. <i>JAMA Oncology</i> , 2015 , 1, 1353	13.4	3
151	Fast-tracking novel drugs in pediatric oncology. <i>Cell Cycle</i> , 2015 , 14, 1127-8	4.7	3
150	Vemurafenib in Patients with Erdheim-Chester Disease (ECD) and Langerhans Cell Histiocytosis (LCH) Harboring BRAFV600 Mutations: A Cohort of the Histology-Independent VE-Basket Study. <i>Blood</i> , 2016 , 128, 480-480	2.2	3
149	Phase 1 dose escalation trial of intravenous radium 223 dichloride alpha-particle therapy in osteosarcoma.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS10600-TPS10600	2.2	3

148	First-in-human dose escalation, safety, and PK study of a novel EFNA4-ADC in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2520-2520	2.2	3
147	Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer. <i>Oncotarget</i> , 2017 , 8, 33796-33806	3.3	3
146	Older adults in phase I clinical trials: a comparative analysis of participation and clinical benefit rate among older adults versus middle age and AYA patients on phase I clinical trials with VEGF/VEGFR inhibitors. <i>Oncotarget</i> , 2018 , 9, 28842-28848	3.3	3
145	Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist. <i>Oncologist</i> , 2019 , 24, 1291-1293	5.7	3
144	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
143	Activity of Brigatinib in Crizotinib and Ceritinib-Resistant Rearranged Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
142	Molecular Profiling of Metastatic Bladder Cancer Early-Phase Clinical Trial Participants Predicts Patient Outcomes. <i>Molecular Cancer Research</i> , 2021 , 19, 395-402	6.6	3
141	The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial. <i>Investigational New Drugs</i> , 2021 , 39, 829-835	4.3	3
140	Current update on gallbladder carcinoma. <i>Abdominal Radiology</i> , 2021 , 46, 2474-2489	3	3
139	Circulating V600E Cell-Free DNA as a Biomarker in the Management of Anaplastic Thyroid Carcinoma.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-11	3.6	3
138	Retrospective Case Series Analysis of Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies. <i>JCO Precision Oncology</i> , 2021 , 5,	3.6	3
137	Review: Ewing sarcoma treatment: a role for bisphosphonates?. <i>Clinical Advances in Hematology and Oncology</i> , 2010 , 8, 503-4	0.6	3
136	Bringing wearable devices into oncology practice: fitting smart technology in the clinic. <i>Discovery Medicine</i> , 2018 , 26, 261-270	2.5	3
135	Vandetanib photoinduced cutaneous toxicities. <i>Cutis</i> , 2019 , 103, E24-E29	0.4	3
134	Molecular imaging of metastatic atrial angiosarcoma with positron emission tomography (PET) tracer 3'-deoxy-3' [F]-fluorothymidine, [F]-FLT imaging and early response evaluation. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	2
133	Comprehensive molecular imaging of malignant transformation of giant cell tumour of bone reveals diverse disease biology. <i>BMJ Case Reports</i> , 2019 , 12,	0.9	2
132	Cancer Genetics and Therapeutic Opportunities in Urologic Practice. <i>Cancers</i> , 2020 , 12,	6.6	2
131	Molecular Imaging with 3'-deoxy-3' [(18)F]-Fluorothymidine (F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study. <i>Diagnostics</i> , 2020 , 10,	3.8	2

130	Immunotherapy and next-generation sequencing guided therapy for precision oncology: What have we learnt and what does the future hold?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2018 , 3, 205-213	1.6	2
129	Incidence and impact of adverse effects of medical care on complications in patients who underwent excision of cervical lymph nodes. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2014 , 118, 271-7	2	2
128	Activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated refractory Hodgkin lymphoma patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 8508-8508	2.2	2
127	Co-targeting BRAF with mTOR inhibition in solid tumors harboring BRAF mutations: A phase I study.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2517-2517	2.2	2
126	Deep sequencing of metastatic cutaneous basal cell and squamous cell carcinomas to reveal distinctive genomic profiles and new routes to targeted therapies.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 9522-9522	2.2	2
125	Phase II study for the evaluation of efficacy of pembrolizumab (MK-3475) in patients with cancer of unknown primary.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS3103-TPS3103	2.2	2
124	Preliminary safety of deep/visceral (D/V) image guided (IG) intratumoral injection (ITI) of IMO-2125.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e15150-e15150	2.2	2
123	Higher mortality in men from COVID19 infection-understanding the factors that drive the differences between the biological sexes		2
122	F-sodium fluoride positron emission tomography (NaF-18-PET/CT) radiomic signatures to evaluate responses to alpha-particle Radium-223 dichloride therapy in osteosarcoma metastases. <i>Current Problems in Cancer</i> , 2021 , 45, 100797	2.3	2
121	Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data. <i>JAMA Network Open</i> , 2021 , 4, e2126306	10.4	2
120	Safety and efficacy of pemigatinib plus pembrolizumab combination therapy in patients (pts) with advanced malignancies: Results from FIGHT-101, an open-label phase I/II study.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3606-3606	2.2	2
119	The Efficacy of Vemurafenib in Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Preliminary Results from VE-Basket Study. <i>Blood</i> , 2014 , 124, 635-635	2.2	2
118	Exclusion of Older Adults in COVID-19 Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2293-2294	6.4	2
117	EZH2 inhibition for epithelioid sarcoma and follicular lymphoma. <i>Lancet Oncology, The</i> , 2020 , 21, 1388-1397		2
116	Dual inhibition of BRAF and mTOR in -mutant pediatric, adolescent, and young adult brain tumors. <i>Journal of Physical Education and Sports Management</i> , 2020 , 6,	2.8	2
115	Precision medicine: preliminary results from the Initiative for Molecular Profiling and Advanced Cancer Therapy 2 (IMPACT2) study. <i>Npj Precision Oncology</i> , 2021 , 5, 21	9.8	2
114	Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study. <i>ESMO Open</i> , 2021 , 6, 100079	6	2
113	Overview of Ocular Side Effects of Selinexor. <i>Oncologist</i> , 2021 , 26, 619-623	5.7	2

112	A Phase I Trial of the MET/ Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies. <i>OncoTargets and Therapy</i> , 2021 , 14, 3037-3049	4.4	2
111	Clinical activity and safety of the RET inhibitor pralsetinib in patients with RET fusion-positive solid tumors: Update from the ARROW trial.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3079-3079	2.2	2
110	Abstract CT025: Dabrafenib plus trametinib in BRAF V600E-mutant high-grade (HGG) and low-grade glioma (LGG) 2021 ,		2
109	Detection and clearance of RET variants in plasma cell free DNA (cfDNA) from patients (pts) treated with LOXO-292. <i>Annals of Oncology</i> , 2018 , 29, viii33	10.3	2
108	Activity of Pemigatinib in Pilocytic Astrocytoma and Mutation.. <i>JCO Precision Oncology</i> , 2022 , 6, e210037316	3.6	2
107	Dabrafenib plus trametinib in patients with BRAF-mutated biliary tract cancer - Authors' reply. <i>Lancet Oncology, The</i> , 2020 , 21, e516	21.7	1
106	Antitumor Response to Combined Antiangiogenic and Cytotoxic Chemotherapy in Recurrent Metastatic Chromophobe Renal Cell Carcinoma: Response Signatures and Proteomic Correlates. <i>Clinical Genitourinary Cancer</i> , 2016 , 14, e187-93	3.3	1
105	How watching the movie <i>Zombieland</i> helps treatment of cancer in teenagers. <i>Journal of Cancer Education</i> , 2012 , 27, 188-91	1.8	1
104	Case 36-2009: A man with cough, hoarseness, and abnormalities on chest imaging. <i>New England Journal of Medicine</i> , 2010 , 362, 961; author reply 961	59.2	1
103	99mTc-sestamibi scan differentiates tumor from other contrast enhancing tissue in choroid plexus tumors. <i>Journal of Pediatric Hematology/Oncology</i> , 2010 , 32, 160-2	1.2	1
102	Corticosteroid-Refractory Myositis After Dual BRAF and MEK Inhibition in a Patient with BRAF V600E-Mutant Metastatic Intrahepatic Cholangiocarcinoma. <i>Journal of Immunotherapy and Precision Oncology</i> , 2022 , 5, 26-30	0.6	1
101	Phase I pharmacokinetic study of single agent trametinib in patients with advanced cancer and hepatic dysfunction.. <i>Journal of Experimental and Clinical Cancer Research</i> , 2022 , 41, 51	12.8	1
100	Significant Activity Of The mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat In Heavily Pretreated Refractory Hodgkin Lymphoma Patients. <i>Blood</i> , 2013 , 122, 3048-3048	2.2	1
99	Optimizing the therapy of desmoplastic small round cell tumor: Combined experience from the two major cancer centers.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 10021-10021	2.2	1
98	Characteristics and outcomes of patients with advanced hepatocellular carcinoma treated on phase I trials.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 281-281	2.2	1
97	Longitudinal monitoring of BRAF V600E mutation in urinary cell-free DNA of patients with metastatic cancers.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e22175-e22175	2.2	1
96	Prospective evaluation of a 409-gene next generation sequencing platform to facilitate genotype-matched clinical trial enrollment.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 3608-3608	2.2	1
95	Participation and response assessment of older adults with advanced cancer treated on phase I trials as compared to middle age and AYA patients: An analysis of 1489 patients.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 10049-10049	2.2	1

94	Outcomes of patients with advanced sarcoma enrolled in clinical trials of pazopanib in combination with histone deacetylase, mTOR, Her2, or MEK inhibitors.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11057-11057	2.2	1
93	Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3022-3022	2.2	1
92	Prevalence of incidental germline pathogenic (PV) and likely pathogenic (LPV) variants in hereditary cancer-related genes identified in matched tumor/normal sequencing of advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1524-1524	2.2	1
91	Vemurafenib in patients with BRAFV600 mutant glioma: A cohort of the histology-independent VE-basket study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2004-2004	2.2	1
90	SWI/SNF complex subunit aberrations in diverse cancers: Next-generation sequencing of 539 patients.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2588-2588	2.2	1
89	A phase 1b dose-escalation study of prexasertib, a checkpoint kinase 1 (CHK1) inhibitor, in combination with cisplatin in patients with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2579-2579	2.2	1
88	Emergence of mTOR mutation as an acquired resistance mechanism to AKT inhibition, and subsequent response to mTORC1/2 inhibition. <i>Npj Precision Oncology</i> , 2021 , 5, 99	9.8	1
87	Call to integrate supportive care and patient reported outcomes in early phase clinical trials: An exploration of adolescent and young adult (AYA) participation on phase I trials of novel anticancer agents.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 149-149	2.2	1
86	Rechallenge with anti-EGFRBased therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3607-3607	2.2	1
85	Eliciting early-response signals from first-in-human clinical trials and validation of prognostic scores in aggressive biology bone cancers: The MD Anderson experience.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10531-10531	2.2	1
84	Phase I study of combination of crizotinib (C) and dasatinib (D) in patients (pts) with advanced cancer.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2597-2597	2.2	1
83	Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2588-2588	2.2	1
82	Low frequency KRAS G12/13 mutations in urine cell-free (cf) DNA from patients with BRAF V600E-mutant advanced cancers.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 11048-11048	2.2	1
81	Combination Therapies for Precision Oncology: The Ultimate Whack-A-Mole Game. <i>Clinical Cancer Research</i> , 2021 , 27, 2672-2674	12.9	1
80	Sequencing PEComas: Viewing Unicorns through the Molecular Looking Glass. <i>Oncology</i> , 2021 , 99, 62-64	3.6	1
79	Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid Tumors. <i>Clinical Cancer Research</i> , 2021 , 27, 1247-1255	12.9	1
78	Effect of lurbectedin on the QTc interval in patients with advanced solid tumors: an exposure-response analysis. <i>Cancer Chemotherapy and Pharmacology</i> , 2021 , 87, 113-124	3.5	1
77	Response to Mammalian Target of Rapamycin-Based Therapy and Incidental Finding of Lynch Syndrome in a Patient With Solid Pseudopapillary Neoplasm of the Pancreas With Mutation. <i>JCO Precision Oncology</i> , 2018 , 2,	3.6	1

76	A Phase I Study of an MPS1 Inhibitor (BAY 1217389) in Combination with Paclitaxel Using a Novel Randomized Continual Reassessment Method for Dose Escalation. <i>Clinical Cancer Research</i> , 2021 , 27, 6366-6375	12.9	1
75	Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial. <i>Oncologist</i> , 2021 ,	5.7	1
74	A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events. <i>Oncology Research and Treatment</i> , 2021 , 44, 547-556	2.8	1
73	ROAR trial: which treatment is effective after progression? - Authors' reply.. <i>Lancet Oncology, The</i> , 2022 , 23, e94	21.7	1
72	Assessment of tumour-agnostic therapies in basket trials.. <i>Lancet Oncology, The</i> , 2022 , 23, e7	21.7	0
71	Diversity and heterogeneity in molecular analysis of advanced sarcomas: The clinical, regulatory, and financial challenge for drug development and precision medicine.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 10595-10595	2.2	0
70	Optimizing anti-body drug conjugates and radiopharmaceuticals for precision therapy: The next frontier in precision oncology. <i>Current Problems in Cancer</i> , 2021 , 45, 100799	2.3	0
69	Discovery of targeted expression data for novel antibody-based and chimeric antigen receptor-based therapeutics in soft tissue sarcomas using RNA-sequencing: clinical implications. <i>Current Problems in Cancer</i> , 2021 , 45, 100794	2.3	0
68	Targeted therapies in early-phase trials for the treatment of advanced fibrolamellar hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 232-232	2.2	0
67	Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi-arm phase Ib study. <i>Investigational New Drugs</i> , 2021 , 39, 1357-1365	4.3	0
66	Headache in a patient with renal cell carcinoma. <i>European Journal of Internal Medicine</i> , 2016 , 32, e3-4	3.9	0
65	Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphoma. <i>ESMO Open</i> , 2021 , 6, 100172	6	0
64	The value of innovation: association between improvements in survival of advanced and metastatic non-small cell lung cancer and targeted and immunotherapy. <i>BMC Medicine</i> , 2021 , 19, 209	11.4	0
63	A phase 2, multiarm study of anti-CD47 antibody, magrolimab, in combination with docetaxel in patients with locally advanced or metastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2022 , 40, TPS584-TPS584	2.2	0
62	Association Between Smoking History and Overall Survival in Patients Receiving Pembrolizumab for First-Line Treatment of Advanced NonSmall Cell Lung Cancer. <i>JAMA Network Open</i> , 2022 , 5, e2214046	10.4	0
61	Patient-Centered, Physician-Investigator Friendly Pragmatic Phase Trial Designs-The 4P Model. <i>Mayo Clinic Proceedings</i> , 2020 , 95, 2566-2568	6.4	
60	Advanced atypical teratoid/rhabdoid tumor (ATRT) treated with intensive multimodal approach shows continued response to sarcoma type salvage therapy. <i>Pediatric Blood and Cancer</i> , 2012 , 58, 823-4 ³		
59	There are still some things money can't buy. <i>Journal of Cancer Education</i> , 2011 , 26, 395-6	1.8	

- 58 A friend request: to accept or decline?. *Journal of Palliative Medicine*, **2010**, 13, 465 2.2
- 57 To ring or wring the bell?. *Journal of Palliative Medicine*, **2011**, 14, 968-9 2.2
- 56 Happy or unhappy christmas?. *American Journal of Hospice and Palliative Medicine*, **2011**, 28, 62 2.6
- 55 Modifiers of risk for infectious complications of cancer therapy in children: the long road ahead. *Pediatric Blood and Cancer*, **2007**, 49, 3-5 3
- 54 Prognostic factors associated with survival in patients with pancreatic cancer treated on early phase immune-checkpoint inhibitor clinical trials.. *Journal of Clinical Oncology*, **2022**, 40, 577-577 2.2
- 53 Analyses of Prognostic Factors for Survival in East African Patients with AIDS-Related Non-Hodgkin Lymphoma (AR-NHL) Treated with Dose Modified Oral Chemotherapy.. *Blood*, **2006**, 108, 3862-3862 2.2
- 52 Clinical Features of Patients with T Cell Large Granular Lymphocyte Leukemia Distinguish Patients with Splenomegaly and Those Who Benefit from Splenectomy.. *Blood*, **2006**, 108, 4467-4467 2.2
- 51 Integration of supportive care in immuno-oncology trials: Investigating the incidence and severity of immune-related toxicities among older adults versus mid-age patients on immunotherapy-based phase I clinical trials.. *Journal of Clinical Oncology*, **2017**, 35, 152-152 2.2
- 50 Hepatotoxicity in advanced cancer patients receiving immune-based cancer treatment.. *Journal of Clinical Oncology*, **2018**, 36, 67-67 2.2
- 49 Analysis of patient related and trial related factors leading to non-participation of patients with advanced cancer in immunotherapy clinical trials: Implications for modifying eligibility criteria.. *Journal of Clinical Oncology*, **2018**, 36, e15066-e15066 2.2
- 48 TP53 mutations and programmed cell death ligand-1 expression in solid tumors: Associations with clinical factors and outcomes.. *Journal of Clinical Oncology*, **2018**, 36, 12052-12052 2.2
- 47 Expanding enrollment of underrepresented populations on early phase clinical trials: An analysis of participation among adolescent and young adults (AYA) with advanced cancers on phase I clinical trials.. *Journal of Clinical Oncology*, **2018**, 36, e18714-e18714 2.2
- 46 A phase I molecular adaptive clinical study to evaluate safety and tolerability of BPM31510-IV in advanced solid tumors: Final study results.. *Journal of Clinical Oncology*, **2018**, 36, 2541-2541 2.2
- 45 Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. *Journal of the National Comprehensive Cancer Network: JNCCN*, **2019**, 17, 886-888 7.3
- 44 Role of Sodium Fluoride-PET in Primary Bone Tumors **2020**, 69-76
- 43 Targeting argininosuccinate synthetase-deficient advanced solid tumors in a phase I trial of ADI-PEG20 plus cisplatin.. *Journal of Clinical Oncology*, **2014**, 32, 2563-2563 2.2
- 42 Local and systemic antitumor effects of activated autologous dendritic cells for intratumoral injection: A phase I/II trial.. *Journal of Clinical Oncology*, **2014**, 32, TPS3133-TPS3133 2.2
- 41 A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.. *Journal of Clinical Oncology*, **2014**, 32, 2576-2576 2.2

- 40 Genomic profiling and precision medicine in 3,745 patients with advanced cancer.. *Journal of Clinical Oncology*, **2014**, 32, e13521-e13521 2.2
- 39 BRAF mutation testing in cell-free DNA from plasma of patients with advanced cancers using a novel, rapid, automated molecular diagnostics platform (Idylla).. *Journal of Clinical Oncology*, **2014**, 32, e22139-e22139 2.2
- 38 A phase I trial of dabrafenib (BRAF inhibitor) and pazopanib in BRAF-mutated advanced malignancies.. *Journal of Clinical Oncology*, **2014**, 32, TPS2628-TPS2628 2.2
- 37 Clinical next-generation sequencing to identify actionable alterations in a phase I program.. *Journal of Clinical Oncology*, **2014**, 32, 11115-11115 2.2
- 36 A phase 1 trial of vandetanib (multikinase inhibitor of EGFR, VEGFR, and RET) in combination with everolimus (mTOR inhibitor) in patients with advanced malignancies.. *Journal of Clinical Oncology*, **2014**, 32, TPS2639-TPS2639 2.2
- 35 Next-generation sequencing in carcinoma of unknown primary (CUP) and novel combinatorial strategies in a heterogeneous mutational landscape: Implications for personalized medicine.. *Journal of Clinical Oncology*, **2014**, 32, e22154-e22154 2.2
- 34 Outcomes of pediatric cancer patients enrolled in phase 1 clinical trials designed for adults: Experience from a major cancer center.. *Journal of Clinical Oncology*, **2014**, 32, e21024-e21024 2.2
- 33 Next-generation sequencing of advanced, relapsed colorectal adenocarcinoma (CRC) to reveal mutations affecting Wnt, MAPK and PI3K pathway signaling: Emergence of novel combinatorial strategies.. *Journal of Clinical Oncology*, **2015**, 33, 605-605 2.2
- 32 Evolution of phase 1 trials for patients with advanced pancreatic cancer: An update on the experience from MD Anderson Cancer Center.. *Journal of Clinical Oncology*, **2015**, 33, 320-320 2.2
- 31 A multicenter phase II basket clinical trial of lurbinectedin (PM01183) in selected advanced solid tumors.. *Journal of Clinical Oncology*, **2015**, 33, TPS2604-TPS2604 2.2
- 30 Phase I study of combination vemurafenib, carboplatin, and paclitaxel in patients (pts) with BRAF-mutant advanced cancer.. *Journal of Clinical Oncology*, **2015**, 33, 105-105 2.2
- 29 Phase I study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancies.. *Journal of Clinical Oncology*, **2015**, 33, 2584-2584 2.2
- 28 Comparison of adult oncology phase 1 trials to pediatric oncology phase 1 trials of targeted therapies.. *Journal of Clinical Oncology*, **2015**, 33, 2581-2581 2.2
- 27 Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy.. *Journal of Clinical Oncology*, **2016**, 34, e21637-e21637 2.2
- 26 Co-occurring genomic alterations and association with progression free survival in BRAFV600 mutated non-melanoma tumors treated with BRAF inhibitor.. *Journal of Clinical Oncology*, **2016**, 34, 2546^{2,3}-2546 2.2
- 25 Symptom clusters in patients with advanced cancer in an early-phase clinical trials clinic.. *Journal of Clinical Oncology*, **2016**, 34, 2540-2540 2.2
- 24 Phase I trial of paclitaxel, bevacizumab, and temsirolimus in advanced solid malignancies.. *Journal of Clinical Oncology*, **2016**, 34, 2573-2573 2.2
- 23 Clinical utilization of precision oncology decision support for genomically-informed cancer therapy.. *Journal of Clinical Oncology*, **2016**, 34, 11605-11605 2.2

22	Clinical next-generation sequencing in sarcomas.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 11046-11046	2.2
21	Personalized Medicine in Hereditary Cancer Syndromes 2017 , 199-225	
20	Hormone receptor (AR/ER/PR) expression as a prognostic marker and novel candidate for drug development across multiple tumor types.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2537-2537	2.2
19	Analysis of osteosarcoma subtypes by clinical genomic testing to identify clinically actionable alterations.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11019-11019	2.2
18	Phase IB study to evaluate the safety of selinexor in combination with multiple standard chemotherapy agents in patients with advanced malignancies.. <i>Journal of Clinical Oncology</i> , 2017 , 35, TPS2603-TPS2603	2.2
17	Pathogenic variants in DNA damage response (DDR) genes in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11567-11567	2.2
16	Clinical next generation sequencing for precision oncology in rare cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2582-2582	2.2
15	Bayesian AI to delineate molecular signatures of patient susceptibility to potential hematologic events in a phase I study of BPM31510 (ubidecarenone) in solid tumors.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e14042-e14042	2.2
14	Proof-of concept phase I study of everolimus, letrozole and trastuzumab in hormone receptor-positive, HER2-positive/amplified or mutant metastatic breast cancer or other solid tumors: Evaluating synergy and overcoming resistance.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2583-2583	2.2
13	Phase I study of nab-paclitaxel, gemcitabine, and bevacizumab in advanced cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2526-2526	2.2
12	Liquid biopsies of plasma exosomal nucleic acids, plasma cell-free DNA, and survival of patients with advanced cancers.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 11551-11551	2.2
11	Immuno-oncology and the elderly: A comparative analysis of participation and toxicities of senior adults aged 65 years and above vs mid age and adolescent/young adult patients on immunotherapy-based phase I clinical trials.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10034-10034	2.2
10	Outcomes of phase I clinical trials for patients with advanced pancreatic cancer: update of the MD Anderson Cancer Center experience. <i>Oncotarget</i> , 2017 , 8, 87163-87173	3.3
9	Biotargets in Sarcomas: The Past, Present, and a Look into the Future 2012 , 419-438	
8	Early-phase trials compared to first- and second-line FDA-approved treatments in patients with advanced gallbladder cancer and cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e13020-e13020	2.2
7	c-Met abnormalities in patients with genitourinary (GU) malignancies and outcomes with c-MET inhibitors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 407-407	2.2
6	Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials. <i>ESMO Open</i> , 2020 , 5, e001073	6
5	The Senses and Cancer. <i>Journal of Palliative Medicine</i> , 2016 , 19, 467-467	2.2

4	Quantification of the Effect of Shuttling on Computed Tomography Perfusion Parameters by Investigation of Aortic Inputs on Different Table Positions From Shuttle-Mode Scans of Lung and Liver Tumors. <i>Journal of Computer Assisted Tomography</i> , 2018 , 42, 357-364	2.2
3	Phase I Trial of Dabrafenib and Pazopanib in Mutated Advanced Malignancies.. <i>JCO Precision Oncology</i> , 2018 , 2, 1-19	3.6
2	Targeted therapy for genetic cancer syndromes: Fanconi anemia, medullary thyroid cancer, tuberous sclerosis, and RASopathies. <i>Discovery Medicine</i> , 2015 , 19, 101-8	2.5
1	Abstract OT2-01-02: First in human phase 1 dose escalation and expansion study of the safety and pharmacokinetics of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients with inoperable locally advanced or metastatic solid tumors, including breast cancer. <i>Cancer Research</i> , 2022 , 82, OT2-01-02-OT2-01-02	10.1